Urology Department, The Oncology Institute "Prof. Dr. Ion Chiricuţă", 400015 Cluj-Napoca, Romania.
Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Arch Esp Urol. 2024 Jan;77(1):43-48. doi: 10.56434/j.arch.esp.urol.20247701.6.
This study aimed to evaluate the indirect effect of the Coronavirus Disease 2019 (COVID-19) pandemic on the surgical outcomes and oncological results of patients who underwent surgery during the lockdown period.
We analysed data from 423 patients who underwent radical prostatectomy between 2016 and 2022, with a cut-off date of March 16, 2020. Patients were categorised into two groups, namely, pre-lockdown (n = 289) and during lockdown (n = 134). Perioperative variables, histopathological findings and oncological outcomes, including prostate-specific antigen (PSA) levels and biochemical recurrence (BCR), were assessed.
The number of radical prostatectomy increased by 24.26% during lockdown. The study included patients with a mean follow-up of 21 months. A nonsignificant trend towards a higher PSA level at presentation was found (14.22 vs. 12.53 ng/dL, = 0.216). The International Society of Urological Pathology grade was not significantly different among radical prostatectomy specimens ( = 0.669). Lymph node involvement increased during the COVID-19 period ( = 0.046). The pT classification in prostatectomy specimens increased during the pandemic, but the difference from the pre-pandemic value was not statistically significant. The BCR rates were 24.6% pre-lockdown and 29.9% during lockdown ( = 0.136).
The COVID-19 pandemic led to poor postoperative results. Through a 2-year follow-up, this research investigated the effect of the pandemic on the oncological outcomes, particularly BCR, of patients who underwent radical prostatectomy. Further extended investigations and multi-institutional studies should be conducted to quantify the effect of the pandemic on various cancer outcomes and inform crisis management strategies.
本研究旨在评估 2019 年冠状病毒病(COVID-19)大流行对封锁期间接受手术治疗的患者的手术结果和肿瘤学结果的间接影响。
我们分析了 2016 年至 2022 年间接受根治性前列腺切除术的 423 名患者的数据,截止日期为 2020 年 3 月 16 日。患者分为两组,即封锁前组(n=289)和封锁期间组(n=134)。评估了围手术期变量、组织病理学发现和肿瘤学结果,包括前列腺特异性抗原(PSA)水平和生化复发(BCR)。
封锁期间,根治性前列腺切除术的数量增加了 24.26%。研究包括平均随访 21 个月的患者。发现在诊时 PSA 水平呈升高趋势,但无统计学意义(14.22 与 12.53ng/dL, = 0.216)。根治性前列腺切除标本的国际泌尿病理学会分级无显著差异( = 0.669)。在 COVID-19 期间,淋巴结受累增加( = 0.046)。前列腺切除标本的 pT 分类在大流行期间增加,但与大流行前值的差异无统计学意义。在封锁前,BCR 发生率为 24.6%,封锁期间为 29.9%( = 0.136)。
COVID-19 大流行导致术后结果不佳。通过 2 年的随访,本研究调查了大流行对接受根治性前列腺切除术患者的肿瘤学结果,特别是 BCR 的影响。应进行进一步的扩展调查和多机构研究,以量化大流行对各种癌症结果的影响,并为危机管理策略提供信息。